Skip to content

The effect of intravenous injection of oxycodone hydrochloride for preemptive analgesia in thoracoscopic surgery with preserved spontaneous respiration

The effect of intravenous injection of oxycodone hydrochloride for preemptive analgesia in thoracoscopic surgery with preserved spontaneous respiration

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076328
Enrollment
Unknown
Registered
2023-10-03
Start date
2023-10-03
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung disease

Interventions

experimental group:The experimental group was given oxycodone hydrochloride injection of 0.1mg/kg, diluted with 0.9% sodium chloride injection to a concentration of 1mg/h, and intravenous injection wa
control group:Administer 50mg of flurbiprofen axetil at the same time point

Sponsors

Dongguan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Perform thoracoscopic surgery with preserved autonomous breathing, including lung segment resection under preserved autonomous breathing thoracoscopy, mediastinal mass resection under preserved autonomous breathing thoracoscopy, and radical lung cancer resection under preserved autonomous breathing thoracoscopy, sign an "informed consent form" and indicate the date;2. Age range from 18 to 65 years old;3. Patient body mass index BMI 18-27 kg/m2;4. The American Society of Anesthesiologists (ASA) is rated as either I or II;5. No major heart, brain, lung, kidney or other diseases

Exclusion criteria

Exclusion criteria: 1. Drug abuse, including but not limited to opioids, amphetamines, methamphetamine, ketamine, etc; 2. Allergies to opioids and contraindications related to investigational drugs: Allergies to oxycodone, non-steroidal anti-inflammatory drugs, or any other components of the drug, chronic obstructive airway disease, pulmonary heart disease, chronic bronchial asthma, and severe hypertension patients; 3. Neurological diseases such as peripheral neuropathy and mental illness; 4. Other situations that the researchers believe are not suitable for participation in this study, such as deafness, Parkinson's disease, communication disorders, etc.

Design outcomes

Primary

MeasureTime frame
Resting NRS pain score;

Secondary

MeasureTime frame
Sufentanil and refentanil consumption;The number of times the patient controls the addition of the intravenous analgesia pump;Additional amounts of analgesic medication;Postoperative adverse effects;

Countries

China

Contacts

Public ContactWeiming Liang

Dongguan People's Hospital

463721302@qq.com+86 159 1314 8625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026